Karas Eric (CIK 1951287) reported 8 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-06-12). Recent activity: Buy SPRY (25,000 shares), Sell SPRY (25,000 shares), Buy SPRY (15,000 shares), Sell SPRY (15,000 shares), Buy SPRY (15,000 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-12 | ARS Pharmaceuticals, Inc. (SPRY) | Chief Commercial Officer | Buy | 25,000 | $37,500 |
| 2026-06-12 | ARS Pharmaceuticals, Inc. (SPRY) | Chief Commercial Officer | Sell | 25,000 | $250,000 |
| 2025-07-03 | ARS Pharmaceuticals, Inc. (SPRY) | Chief Commercial Officer | Buy | 15,000 | $22,500 |
| 2025-07-03 | ARS Pharmaceuticals, Inc. (SPRY) | Chief Commercial Officer | Sell | 15,000 | $254,850 |
| 2025-06-20 | ARS Pharmaceuticals, Inc. (SPRY) | Chief Commercial Officer | Buy | 15,000 | $22,500 |
| 2025-06-20 | ARS Pharmaceuticals, Inc. (SPRY) | Chief Commercial Officer | Sell | 15,000 | $240,000 |
| 2025-03-21 | ARS Pharmaceuticals, Inc. (SPRY) | Chief Commercial Officer | Buy | 10,000 | $15,000 |
| 2025-03-21 | ARS Pharmaceuticals, Inc. (SPRY) | Chief Commercial Officer | Sell | 10,000 | $140,000 |
Source: SEC Form 4 filings · as of 2026-06-12